Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Endocrinol Metab. 2014 Jun;99(6):1983-92. doi: 10.1210/jc.2014-1425. Epub 2014 Apr 8.

β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment.

Author information

1
Department of Genetic Medicine and Development (P.A.H.), University of Geneva, Geneva, Switzerland; Department of Medicine (K.S.P.), Section of Endocrinology, University of Chicago, Chicago, IL 60637; Center for Genomics and Personalized Medicine Research and Center for Diabetes Research (D.W.B.), Wake Forest University, Winston-Salem, NC 27106; Department of Medicine (Endocrinology) and Global Diabetes Institute (M.A.H.), Albert Einstein College of Medicine, Bronx, NY 10461; Department of Clinical Sciences, Lund University (C.L.), Lund, Sweden; Department of Endocrinology (K.J.M.), Indiana University, Indianapolis, IN 46202; Division of Diabetes (A.C.P.), Endocrinology and Metabolism, Vanderbilt University School of Medicine, Nashville, TN 37232; Kovler Diabetes Center (C.J.R.), Department of Medicine, University of Chicago, Chicago, IL 60637; Naomi Berrie Diabetes Center (L.S.), Columbia University, New York, NY 10027; and Joslin Diabetes Center (G.C.W.), Harvard Medical School, Boston, MA 02215.

Abstract

OBJECTIVE:

This article examines the foundation of β-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment.

RESEARCH DESIGN AND METHODS:

A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations.

RESULTS:

The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of β-cell failure, natural history of β-cell failure, and impact of therapeutic interventions.

CONCLUSIONS:

β-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to 1) impact the natural history of β-cell failure; 2) identify and characterize genetic loci for T2D; 3) target β-cell signaling, metabolic, and genetic pathways to improve function/mass; 4) develop alternative sources of β-cells for cell-based therapy; 5) focus on metabolic environment to provide indirect benefit to β-cells; 6) improve understanding of the physiology of responses to bypass surgery; and 7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells.

PMID:
24712577
PMCID:
PMC5393482
DOI:
10.1210/jc.2014-1425
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center